CAMP4 Therapeutics priced a 5 million‑share underwritten equity offering at $6.00 per share, generating $30 million in gross proceeds. The transaction is expected to close on December 19, 2025.
The capital raise expands the company’s cash balance, providing additional runway for preclinical development and potential clinical milestones. Proceeds will fund ongoing development of RNA‑targeting therapeutics and general corporate needs, strengthening the firm’s liquidity profile and supporting its high current ratio of 9.83.
The offering coincides with a strategic collaboration with GSK announced the same day. GSK will provide an upfront payment of $17.5 million and potential milestone payments and royalties, validating CAMP4’s proprietary RAP Platform and supporting the development of antisense oligonucleotide candidates for neurodegenerative and kidney diseases.
President and CEO Josh Mandel‑Brehm said the partnership underscores the platform’s potential to create transformational medicines. He added that the equity offering will give the company the financial flexibility to advance its lead candidate, CMP‑SYNGAP‑01, into toxicology studies and eventually a first‑in‑human Phase 1/2 trial in 2026.
With the new capital, CAMP4 can accelerate its pipeline, maintain its strong liquidity, and pursue additional collaborations. The move positions the company to capitalize on the growing RNA therapeutics market while managing dilution risk through a disciplined capital structure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.